Wanhai Medical Secures RMB 100 Million Investment from IDG Capital; Fujifilm Partners with Us2.ai for AI-Powered Echocardiography Analysis

Mar 31, 2025 06:20 CST Updated 06:20

Wanhai Medical

Self-Medication Injection System Solutions Provider

Us2.ai

Developer of Cardiac Risk Detection Tools

Medtronic

Medical Device Manufacturer

Ozda Official AccountmedicaldeviceCRO

Follow and StarEnsure you receive push notifications on time.

Comprehensive Medical Information

1. The Ministry of Industry and Information Technology supports Zhongguancun in accelerating the construction of a world-leading technology park.

Recently, at the 2025 Zhongguancun Forum Annual Conference's World-Leading Science and Technology Park Development Forum, the Ministry of Industry and Information Technology stated that national high-tech zones have adhered to the development of advanced technology and industrialization, forging a path of high-tech industrialization with Chinese characteristics. As China’s first national high-tech zone, Zhongguancun stands as a banner of the country’s scientific and technological innovation. The state supports Zhongguancun in taking innovative demands as guidance and planning a new round of pilot reforms. The Ministry of Industry and Information Technology expressed that it would work with relevant departments and the city of Beijing to implement the "Zhongguancun World-Leading Science and Technology Park Construction Plan (2024–2027)" and support Zhongguancun in taking the lead and setting an example in developing new productive forces, accelerating its transformation into a world-leading science and technology park. (China Securities Journal)

2. The appointment rate for outpatient visits at tertiary public hospitals in China rises to 67.72%.

Recently, Seven Departments Including the National Health Commission Jointly Released the "2023 National Performance Monitoring and Analysis Report of Tertiary Public Hospitals in China". The monitoring results show that the average appointment treatment rate for outpatients in 2,168 tertiary public hospitals in China reached 67.72%, with continuous improvement in patient satisfaction. The monitoring results indicate that in 2023, the medical service efficiency of tertiary public hospitals in China steadily improved. The average appointment treatment rate for outpatients reached 67.72%, increasing by 6.67 percentage points compared to 2022; the average appointment waiting time was controlled within 20 minutes, and the bed utilization rate reached 88.49%. The hierarchical diagnosis and treatment system achieved remarkable results, with tertiary hospitals transferring 31.37 million patients to primary medical institutions throughout the year, a year-on-year increase of 31.40%. Patient satisfaction continued to improve, with outpatient and inpatient satisfaction scores rising to 93.95 and 95.42, respectively. (Beijing Evening News Online)

3. Medtronic's Digital Healthcare Innovation Base in China Launched at BioPark

Recently, the signing and unveiling ceremony of Medtronic's Digital Healthcare Innovation Base was held at the International Pharmaceutical Innovation Park (BioPark). This marks the establishment of Medtronic’s first digital healthcare innovation base in China, signifying a new chapter in its development in Beijing. The base is dedicated to developing disease management solutions based on artificial intelligence and big data, with a focus on building medical training centers in areas such as cardiovascular, minimally invasive surgery, and neuroscience. It will also establish a patient care center, incorporating digital technologies to enhance service levels in preventive patient management, while constructing the Medtronic Museum. The innovation base is scheduled to officially begin operations by the end of this year. (Yizhuang, Beijing)

4. Yifeng Pharmacy Establishes New Company with AI Software Development Business

Recently, Yifeng Pharmacy, a listed chain pharmacy, has made a new move by establishing a new company — Jin Kang Medical Technology (Hainan) Co., Ltd. According to the Qichacha APP, the legal representative of Jin Kang Medical Technology (Hainan) Co., Ltd. is Wang Yonghui, with a registered capital of 1 million yuan. The business scope covers multiple fields including artificial intelligence (AI) application software development, information technology consulting services, health consulting services (excluding medical treatment services), and AI public data platforms. Qichacha's equity penetration shows that the company is wholly owned by Yifeng Pharmacy. This move indicates that Yifeng Pharmacy has officially made AI technology a key focus of its development, marking another significant step in the company’s digital transformation and health service upgrade. (MENET Retail Observation)

5. Fujifilm Collaborates with Us2.ai

Recently, Fujifilm has been collaborating with Singapore-based Us2.ai to integrate the company's AI-based image analysis software into the LISENDO 880 and LISENDO 800 cardiovascular ultrasound systems for diagnosing heart disease. Us2.ai’s software will analyze images acquired through Fujifilm’s ultrasound systems, reducing the manual analysis processes that clinicians previously had to perform. The software performs fully automated analyses of all cardiac chambers using 2D and Doppler views and captures a range of other clinically significant measurements. Once the image analysis is completed, Us2.ai’s software provides clinicians with disease indicator conclusions based on international guidelines and recommendations to guide the next steps in treatment. (Medical Device Network)

6. ReFlow® Ventricular Drainage Catheter Receives FDA Breakthrough Device Designation

Recently, Anuncia Medical, a company focused on cerebrospinal fluid management and neurocritical care, announced that its innovative external ventricular drain (EVD) solution, the ReFlow® EVD, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The device is used to manage brain swelling and elevated intracranial pressure. This milestone expands Anuncia's portfolio of breakthrough products, complementing the first-generation device, the ReFlow® System Mini (with up to six years of clinical success), and the ReFlow® Mini Flusher, which, upon its early U.S. launch, has already transformed hydrocephalus care by enabling non-invasive, home-based cerebrospinal fluid flow maintenance and reducing the need for costly revision surgeries. (CISION)

7. What is the medical device public service platform?

The Medical Device Public Service Platform, jointly developed by the Ozoda Group with local governments, parks, medical institutions, and research universities, focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technology projects. By establishing a scientific research and transfer mechanism aligned with international standards, it implements an open and shared operational model to attract top-tier scientific researchers, doctors, and innovators worldwide. The platform provides comprehensive industry technical services integrating R&D transformation, incubation, and investment, fostering innovative medical device achievements with significant innovation and application value, thereby strongly supporting the development of the medical device industry and technological innovation. (Compiled by Ozoda)

8. Injection Pen Manufacturer "Wanhai Medical" Receives USD 100 Million Investment from IDG Capital

Recently, Jiangsu Wanhai Medical Device Co., Ltd. announced the completion of a billion-yuan financing round, exclusively invested by IDG Capital, with SourceOne Capital serving as the exclusive financial advisor. This funding will enable Wanhai Medical to further expand its annual production capacity from the current 90 million units to 310 million units, forming an automated and intelligent injection pen production base with a total capacity of 400 million units. Established in 2016, Wanhai Medical is headquartered in West Taihu Lake, Changzhou, Jiangsu, with a branch in Shanghai. It is a national high-tech enterprise and a specialized and innovative enterprise. Currently, Wanhai Medical has the capability to stably mass-produce 90 million disposable and reusable injection pens annually, forming a vertically integrated industrial chain layout encompassing mold manufacturing, processing and injection molding, automated assembly, and testing and inspection. (Investment Community)